Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 26,100Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 7Bevespi

02 5Breztri

03 2Lonhala Magnair

04 6Seebri Breezhaler

05 2Ultibro Breezhaler

06 3Ultibro Group

PharmaCompass

01

Brand Name : Lonhala Magnair

Glycopyrrolate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Lonhala Magnair

arrow
2024 ACI Convention
Not Confirmed

Glycopyrrolate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 22

2019 Revenue in Millions : 17

Growth (%) : 28

blank

02

arrow
2024 ACI Convention
Not Confirmed

03

Brand Name : Bevespi

Glycopyrrolate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Bevespi

arrow
2024 ACI Convention
Not Confirmed

Glycopyrrolate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 48

2019 Revenue in Millions : 42

Growth (%) : 14

blank

04

Brand Name : Bevespi

Glycopyrrolate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Bevespi

arrow
2024 ACI Convention
Not Confirmed

Glycopyrrolate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2021 Revenue in Millions : 54

2020 Revenue in Millions : 48

Growth (%) : 13

blank

05

Brand Name : Breztri

Glycopyrronium

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Breztri

arrow
2024 ACI Convention
Not Confirmed

Glycopyrronium

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2021 Revenue in Millions : 203

2020 Revenue in Millions : 28

Growth (%) : 625

blank

06

Brand Name : Ultibro Group

Glycopyrronium Bromide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Ultibro Group

arrow
2024 ACI Convention
Not Confirmed

Glycopyrronium Bromide

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 623

2019 Revenue in Millions : 630

Growth (%) : -1

blank

07

Brand Name : Ultibro Group

Glycopyrronium Bromide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Ultibro Group

arrow
2024 ACI Convention
Not Confirmed

Glycopyrronium Bromide

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2021 Revenue in Millions : 584

2020 Revenue in Millions : 623

Growth (%) : -6

blank

08

Brand Name : Ultibro Group

Glycopyrronium

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Ultibro Group

arrow
2024 ACI Convention
Not Confirmed

Glycopyrronium

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2022 Revenue in Millions : 479

2021 Revenue in Millions : 584

Growth (%) : -18

blank

09

Brand Name : Bevespi

Glycopyrrolate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Bevespi

arrow
2024 ACI Convention
Not Confirmed

Glycopyrrolate

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2022 Revenue in Millions : 58

2021 Revenue in Millions : 54

Growth (%) : 7

blank

10

Brand Name : Breztri

Glycopyrronium

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Breztri

arrow
2024 ACI Convention
Not Confirmed

Glycopyrronium

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2022 Revenue in Millions : 398

2021 Revenue in Millions : 203

Growth (%) : 96

blank